Abstract
In England, the National human papillomavirus (HPV) immunisation programme was introduced in 2008 to prevent cervical cancer. Girls aged 12 to 13 were offered routine vaccination, and those aged 14 to 18 years in 2008 were offered ‘catch-up’ vaccination. Using Census 2011, Hospital Episode Statistics and mortality data for the population of England, we exploit the cut-off in eligibility and apply a regression discontinuity design (RDD) to assess the impact of HPV vaccination on cervical disease. Vaccination reduced the incidence of cervical dysplasia and cancer diagnoses by 31% and 75% respectively at ages 23 to 30 years in girls offered catch-up vaccination at ages 17 to 18 years compared to those who were just above the eligibility age for the catch-up vaccination, with a clear discontinuity. Reductions continued amongst girls offered routine vaccination. These estimates obtained with a quasi-experimental approach are similar to vaccine effectiveness estimates based on more traditional approaches. This novel approach provides further evidence of the HPV vaccination programme reducing adverse cervical outcomes in young women and could be used for future studies to evaluate major changes in HPV vaccination policy and for studies of longer-term outcomes including other cancers and deaths.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval was obtained from the National Statistician's Data Ethics Advisory Committee.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
In accordance with NHS Digital's Information Governance requirements, the study data cannot be shared.